This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
OPKO Health (OPK) Q3 Earnings and Revenues Top Estimates
by Zacks Equity Research
OPKO Health (OPK) delivered earnings and revenue surprises of 500.00% and 26.88%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?
OPKO (OPK) BLA Review for Growth Hormone Deficiency Drug Delayed
by Zacks Equity Research
The FDA extends the PDUFA action date for OPKO (OPK)/Pfizer's BLA for somatrogon to treat pediatric patients with growth hormone deficiency. The review period has been further extended by three months.
OPKO Health (OPK) Forms JV, Establishes Presence in China
by Zacks Equity Research
OPKO Health (OPK) forms a new JV with LeaderMed to establish a presence in China through expansion of the global availability of two of the former's long-acting development products.
OPKO Health's (OPK) Arm Boosts Prenatal Screening With Buyout
by Zacks Equity Research
OPKO Health's (OPK) BioReference's acquisition to expand its NIPS offerings and thereby enhance prenatal screening.
OPKO Health's (OPK) Q2 Earnings Lag Estimates, Margins Down
by Zacks Equity Research
OPKO Health's (OPK) second-quarter results benefit from strength in both its reportable segments.
OPKO Health (OPK) Reports Q2 Loss, Misses Revenue Estimates
by Zacks Equity Research
OPKO Health (OPK) delivered earnings and revenue surprises of -250.00% and -3.31%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?
Earnings Preview: OPKO Health (OPK) Q2 Earnings Expected to Decline
by Zacks Equity Research
OPKO Health (OPK) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
OPKO Health (OPK) Inks Licensing Deal for AntagoNAT Technology
by Zacks Equity Research
OPKO Health's (OPK) latest licensing agreement is expected to advance the development and commercialization of potential disease-modifying therapeutics, especially for Dravet syndrome.
OPKO Health (OPK) and Nicoya Sign RAYALDEE Deal
by Zacks Equity Research
OPKO Health's (OPK) subsidiary EirGen Pharma to develop and commercialize RAYALDEE in Greater China in collaboration with an affiliate of Nicoya Therapeutics.
OPKO Health (OPK) Inks Agreement to Sell Its Ireland Facility
by Zacks Equity Research
OPKO Health (OPK) expects to improve its business efficacy and focus on oral solid dose products post the sale of its Ireland facility.
Why Is OPKO Health (OPK) Down 5.6% Since Last Earnings Report?
by Zacks Equity Research
OPKO Health (OPK) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Is the Options Market Predicting a Spike in OPKO Health (OPK) Stock?
by Zacks Equity Research
Investors need to pay close attention to OPKO Health (OPK) stock based on the movements in the options market lately.
OPKO Health (OPK) Q1 Earnings Match Estimates, Revenues Top
by Zacks Equity Research
OPKO Health's (OPK) first-quarter results benefit from strength in diagnostics.
OPKO Health (OPK) Meets Q1 Earnings Estimates
by Zacks Equity Research
OPKO Health (OPK) delivered earnings and revenue surprises of 0.00% and 8.39%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?
OPKO Health's (OPK) BioReference Extends Sports Partnerships
by Zacks Equity Research
OPKO Health's (OPK) BioReference expands its major league sports relationships with the announcement of COVID-19 testing agreement with MLB.
OPKO Health (OPK) BioReference Extends COVID-19 School Testing
by Zacks Equity Research
OPKO Health's (OPK) BioReference expands COVID-19 testing in schools to create a safer learning environment for students, teachers, staff and their families.
OPKO Health (OPK) Down 9.5% Since Last Earnings Report: Can It Rebound?
by Zacks Equity Research
OPKO Health (OPK) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
OPKO Health (OPK) Q4 Earnings and Revenues Beat Estimates
by Zacks Equity Research
OPKO Health's (OPK) fourth-quarter results benefit from strength in diagnostics.
OPKO Health (OPK) Q4 Earnings and Revenues Surpass Estimates
by Zacks Equity Research
OPKO Health (OPK) delivered earnings and revenue surprises of 25.00% and 13.41%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?
OPKO Health (OPK) to Report Q4 Earnings: What's in Store?
by Zacks Equity Research
OPKO Health's (OPK) fourth-quarter results are likely to reflect solid performance from Services and Products segment and RAYALDEE.
OPKO Health's (OPK) BioReference Extends Digital Health Access
by Zacks Equity Research
OPKO Health's (OPK) BioReference introduces an in-home, fully-integrated digital platform providing access to diagnostic services.
OPKO Health (OPK) Outpaces Stock Market Gains: What You Should Know
by Zacks Equity Research
OPKO Health (OPK) closed the most recent trading day at $4.48, moving +1.82% from the previous trading session.
OPKO Health's (OPK) BioReference Starts Fan Testing Program
by Zacks Equity Research
OPKO Health's (OPK) BioReference commences mandatory, large-scale COVID-19 testing programs for fans for AFC Division Wild Card playoff game.
OPKO Health (OPK) Loses 16.2% Despite In-Line Q3 Earnings
by Zacks Equity Research
OPKO Health's (OPK) third-quarter results benefit from increase in RAYALDEE prescriptions.
OPKO Health (OPK) Matches Q3 Earnings Estimates
by Zacks Equity Research
OPKO Health (OPK) delivered earnings and revenue surprises of 0.00% and 14.07%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the stock?